Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Research activity and capability in the European reference network MetabERN

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. An ontological foundation for ocular phenotypes and rare eye diseases

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Impaired lipolysis in propionic acidemia: A new metabolic myopathy?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Increased risk of sudden death in untreated Primary Carnitine Deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Late-onset MADD: a rare cause of cirrhosis and acute liver failure?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Danish expanded newborn screening is a successful preventive public health programme

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jean-Michel Heard
  • Cinzia Bellettato
  • Corine van Lingen
  • Maurizio Scarpa
  • MetabERN collaboration group
  • Allan Meldgaard Lund (Medlem af forfattergruppering)
Vis graf over relationer

BACKGROUND: MetabERN is one of the 24 European Reference Networks created according to the European Union directive 2011/24/EU on patient's rights in cross border healthcare. MetabERN associates 69 centres in 18 countries, which provide care for patients with Hereditary Metabolic Diseases, and have the mission to reinforce research and provide training for health professionals in this field. MetabERN performed a survey in December 2017 with the aim to produce an overview documenting research activities and potentials within the network. As the centres are multidisciplinary, separated questionnaires were sent to the clinical, university and laboratory teams. Answers were received from 52 out of the 69 centres of the network, covering 16 countries. A descriptive analysis of the information collected is presented.

RESULTS: The answers indicate a marked interest of the respondents for research, who expressed high motivation and commitment, and estimated that the conditions to do research in their institution were mostly satisfactory. They are active in research, which according to several indicators, is competitive and satisfies standards of excellence, as well as the education programs offered in the respondent's universities. Research in the centres is primarily performed in genetics, pathophysiology, and epidemiology, and focuses on issues related to diagnosis. Few respondents declared having activity in human and social sciences, including research on patient's quality of life, patient's awareness, or methods for social support. Infrastructures offering services for medical research were rarely known and used by respondents, including national and international biobanking platforms. In contrast, respondents often participate to patient registries, even beyond their specific field of interest.

CONCLUSIONS: Taken as a whole, these results provide an encouraging picture of the research capacities and activities in the MetabERN network, which, with respect to the number and representativeness of the investigated centres, gives a comprehensive picture of research on Hereditary Metabolic Diseases in Europe, as well as the priorities for future actions. Marginal activity in human and social sciences points out the limited multidisciplinary constitution of the responding teams with possible consequences on their current capability to participate to patient's empowerment programs and efficiently collaborate with patient's advocacy groups.

OriginalsprogEngelsk
TidsskriftOrphanet Journal of Rare Diseases
Vol/bind14
Udgave nummer1
Sider (fra-til)119
ISSN1750-1172
DOI
StatusUdgivet - 2019

ID: 58995194